vision issues with tirzepatide Semaglutide, Linked to Small Increase in Eye Disorder Risk Comparative ocular outcomes of tirzepatide

concluded GLP-1 treatments led to better quality of life and fewer flare ups for HS patients

Caloric restriction or resveratrol supplementation and ageing in a non-human primate: first-year outcome of the RESTRIKAL study in Microcebus murinus

According to data from the 72-week SURMOUNT-1 trial, participants on the maximum dose experienced an average weight loss of 18% of their body weight , with 36.2% achieving a significant reduction in weight[1]

Employers Are Rewriting Their Chronic Condition Strategies Across industries, employers are shifting from a medication-first model to a more balanced, integrated approach that includes: evidence-based digital therapeutics metabolic health programs behavioral health integration structured care navigation targeted GLP-1 coverage criteria This strategy supports employees more holistically while helping employers manage rising costs

J.AbrieC.Al-HasaniK.BattyM

N Engl J Med 377:206372